As families in Europe clamor for gene therapy, Novartis creates a lottery
The move drew criticism from patient groups over concerns the lottery system would unfairly forsake babies who are at risk from dying from the rare disease.
Related Articles
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and…
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and…
Pan-viral ORFs discovery using massively parallel ribosome profiling
Defining viral proteomes is crucial to understanding viral life cycles and immune recognition but the landscape of translated regions remains unknown for most viruses. We…
Infant receives the first customized CRISPR therapy
Nature Biotechnology – Infant receives the first customized CRISPR therapy
Organoid culture promotes dedifferentiation of mouse myoblasts into stem cells capable of complete muscle regeneration
Nature Biotechnology – Mouse stem cells that regenerate muscle are derived by organoid dedifferentiation of myoblasts.
New tool improves the detection of hidden genetic mutations
The tool, described in Nature Biotechnology, will help understand how changes in our DNA affect proteins and ultimately contribute to cancer, neurodegenerative diseases, and other…
Rapid generation of functional vascular organoids via simultaneous transcription factor activation of endothelial and mural lineages
Melero-Martin and colleagues developed a rapid method to generate vascular organoids from human iPSCs by orthogonally activating the transcription factors ETV2 and NKX3.1. This strategy…
Go fund a brain gain
Nature Biotechnology – The gutting of US research funding represents a once-in-a-generation opportunity for Europe to boost world-class research deprioritized by the Trump administration.
Identification of non-canonical peptides with moPepGen
Nature Biotechnology – moPepGen enables the detection of peptides across species, proteases and technologies.